7-(2-thienyl)-7-deazaadenosine

AB61 (7-(2-thienyl)-7-deazaadenosine) is a potent nucleoside cytostatic agent developed by the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague) and Palacky University in Olomouc. It exhibits nanomolar cytotoxic activity against various cancer cell lines (such as SK-OV-3, BT-549, HT-29, and MDA-MB-231) while showing low toxicity toward normal fibroblasts. This selectivity is due to the efficient phosphorylation of AB61 by adenosine kinase (ADK) in cancer cells, whereas phosphorylation in normal fibroblasts is inefficient. Once phosphorylated to its active triphosphate form, AB61 is incorporated into both cellular DNA and RNA. Its incorporation into DNA induces double-strand breaks and triggers apoptosis, while its random incorporation into RNA blocks translation and inhibits protein synthesis. AB61 has demonstrated significant antitumor efficacy in multiple in vivo mouse xenograft models and is under preclinical development as an anticancer therapeutic.

Other names

7-(2-Thienyl)-7-deazaadenosine